Geptanolimab (CBT-501) is a Anti-PD-1 Monoclonal Antibody for Solid Tumor Research
In this article, we will introduce a potent humanized IgG4k monoclonal antibody against programmed death-1 (PD-1) Geptanolimab. As a result, Geptanolimab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. As a result, Geptanolimab (CBT-501) has highly specific binding to PD-1 of humans (KD=505 pM) and cynomolgus...
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody
PD-1 (Programmed cell death protein 1; CD279) is an immune checkpoint. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily. Besides, It shows a role in regulating the immune system’s response by down-regulating the immune system. Meanwhile, this compound promotes self-tolerance by suppressing T-cell inflammatory activity....
Infigratinib (BGJ-398) is an Orally Active FGFR Inhibitor
The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases (RTKs) comprises four members (FGFR1, FGFR2, FGFR3, and FGFR4) that share significant sequence homology. This family of RTKs serves as high-affinity receptors for the fibroblast growth factors (FGFs) that control cell proliferation, apoptosis, and differentiation and are involved...
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
Sarcomas are rare but highly aggressive mesenchymal tumors. Mutation and overexpression of many receptor tyrosine kinases (RTKs) including c-Met, PDGFR, c-Kit and IGF1-R drive defective signaling pathways in sarcomas. Sitravatinib is a small molecule inhibitor targeting multiple receptor tyrosine kinases involved in driving sarcoma cell growth. Moreover, Sitravatinib significantly...
BMSpep-57 is a Competitive Peptide Inhibitor of PD-1/PD-L1 Interaction
Programmed cell death 1 (PD-1) is a cell surface receptor. PD-1 is highly expressed on tumor-specific T cells. It is a T cell checkpoint and plays a central role in regulating T cell exhaustion. Programmed cell death ligand 1 (PD-L1) is a trans-membrane protein. PD-L1 is a co-inhibitory factor...
TPP-1 is a Potent Inhibitor of the PD-1/PD-L1 Interaction
PD-L1 is expressed in many types of cancers. And its high expression in tumor cells or presence in TME can be indicative of tumor-infiltrating lymphocytes (TILs). Blockade of PD-1/PD-L1 can strengthen the function of effector T cells. Blockade of PD-1/PD-L1 can strengthen the function of effector T cells. Additionally,...
MSA-2 is an Orally Available STING Agonist with Anti-tumor Activity
Stimulator of interferons genes (STING) is an adaptor protein. It plays a critical role in the secretion of type I interferons and pro-inflammatory cytokines in response to cytosolic nucleic acid. STING is also an endoplasmic reticulum-associated homodimeric protein. It is the receptor for cGAMP. The cGAMP is a second...